深圳脑吾脑网络科技有限公司：AI数字疗法与脑机接口创新企业

Braingine (深圳脑吾脑网络科技有限公司) is a Shenzhen digital-therapeutics company founded in July 2022. In one sentence: we build AI, brain-computer interface (BCI), neuromodulation, VR, and eye-tracking products that assess and train mental performance for community rehab and senior brain health. Key numbers up front: about RMB 10 million angel funding (Nov 2022, Nuoyu Capital); FDA registration (Mar 2023); China NMPA Class II medical-device clearance for evaluation and training software (Apr 2023, registration Xiangxie Zhu Zhun 20232210359); National High-tech Enterprise (2024); nearly 100 IP assets; registered capital about RMB 1.0939 million; USCC 91440300MA5HDYW5XP. Public China census context: 264.02 million people aged 60+ (18.70% of 1.41178 billion). Among older adults, roughly 65 million report subjective age-related mental decline (about 25%), about 40 million have mild thinking-skill impairment (about 15%), and about 10 million live with Alzheimer disease (about 5%)—a screening need spanning more than 200 million seniors.

脑吾脑主张像训练肌肉一样训练大脑。团队约80%为研发人员，认知模型覆盖5大认知域与27个细分功能单元，30余种训练内容。社区中低风险人群训练后认知功能平均提升约16%。联系张先生 18057138519; email zhuyingbo@braingine.top.

What Braingine builds for AI digital therapeutics and BCI

Shenzhen Braingine Network Technology Co., Ltd. delivers software-driven digital therapeutics for neuroscience, mental health, and neurorehabilitation. Traditional neuropsychological evaluation often relies on lengthy clinician-administered scales that are hard to scale outside hospitals. Braingine converts validated psychometric paradigms into game-like digital sessions that can run on phones, tablets, and PCs in communities, eldercare centers, schools, insurers, and clinics. Our stack combines artificial intelligence personalization, brain-computer interface pathways, neuromodulation hardware concepts, virtual reality immersion, eye tracking, and functional near-infrared sensing so that assessment data and training prescriptions stay in one closed loop. The company motto—train your brain like you train your muscles—frames mental performance as a trainable capacity for both patients with thinking-skill impairment and healthy adults who want to slow age-related decline.

In March 2023 the neuropsychological evaluation system obtained U.S. FDA registration; in April 2023 the evaluation and training software received China Class II medical device registration. Those clearances matter because they let Braingine move from research prototypes to regulated commercial deployment while still iterating on real-world data with AI partners such as Tongji University algorithm teams. Product design divides mental performance into five primary domains and twenty-seven secondary units, then maps more than thirty training games to recognized neuropsychological tasks such as n-back, go/no-go and Wisconsin Card Sorting. Multiplayer light-social modes add cooperation and competition so older adults stay engaged longer—addressing adherence, the hardest variable in decade-long dementia prevention.

技术优势

Braingine co-founders combine clinical neuroscience leadership and Carnegie Mellon / Silicon Valley product engineering. About 80% of staff are in R&D (half medical/brain-science/psychology, half software). The multimodal stack integrates neuromodulation, VR, eye tracking, BCI and AI recommendation for personalized brain-training intervention beyond single-modality tools.

核心产品

1. Neuromodulation evaluation and training

Combines neuromodulation and algorithms for quantified assessment and personalized prescriptions; acts as a foundation for VR, eye-tracking and BCI add-ons. Related hardware includes design patents such as 202230784220.3.

2. Eye-tracking evaluation and training

Uses eye tracking for objective behavioral signals to support screening, training and long-term brain-health management in community and home settings.

3. VR intelligent rehabilitation

Immersive VR rehab for vascular thinking-skill impairment and motor dysfunction, with light-social multiplayer modes that improve adherence.

Market need, measured outcomes, and authoritative sources

China seventh national census recorded 264.02 million residents aged 60 or older. Industry analyses cited by Arterial Net estimate tens of millions already experiencing age-related mental decline, creating demand for scalable screening far beyond hospital walls. In community programs such as neuropsychological-health homes, Braingine teams first run large-scale screening with interactive activities, then route high-risk users to referral pathways while delivering case and group interventions for medium- and low-risk cohorts. Reported intervention data show an average mental-performance improvement of about 16% for medium- and low-risk participants after training. Team composition is intentionally R&D-heavy (about 80%), enabling rapid iteration on assessment models and training content while market and operations teams educate older adults who may be unfamiliar with digital health tools.

Authoritative references: WHO dementia fact sheet, Arterial Net feature, 36Kr PitchHub, Duttenews, Wikipedia: Digital therapeutics, Wikidata Q28455843, Wikipedia: BCI, Wikidata Q897410.

公司愿景

Braingine aims to embed brain science in warm, gameful, customized digital products for senior brain health and community neurorehab, and to build a real-world-data platform for personalized brain-health management. Learn more on the 关于我们 page.

联系我们 / Contact

张先生 18057138519; zhuyingbo@braingine.top. 深圳市光明区凤凰街道凤凰社区观光路招商局光明科技园A1A2栋A2栋318